Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model
2000
Improving Breast Cancer Treatment with Combined Therapies
publication
Author Information
Author(s): Scott K A, Holdsworth H, Balkwill F R, Dias S
Primary Institution: Biological Therapies Laboratory, Imperial Cancer Research Fund
Hypothesis
Can alternating treatments of IL-12 and a matrix metalloprotease inhibitor improve therapeutic efficacy without chronic toxicity?
Conclusion
The combination of IL-12 and the MMP inhibitor BB94 increased treatment efficacy while reducing chronic toxicity.
Supporting Evidence
- IL-12 induced tumour regression and cure in a murine breast cancer model.
- Long-term IL-12 treatment was associated with chronic toxicity.
- BB94 prevented regeneration of tumour and stromal compartments after short-term IL-12 therapy.
Takeaway
Researchers found that using two different treatments together can help fight breast cancer better and with fewer side effects.
Methodology
Mice were treated with alternating cycles of IL-12 and the MMP inhibitor Batimastat.
Participant Demographics
Murine (mouse) model
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website